|Articles|June 1, 2002
ISTA acquires rights to 3 ophthalmic compounds
Irvine, CA-ISTA Pharmaceuticals, Irvine, CA, entered into an agreement with AcSentient Inc. under which ISTA will acquire rights to three late-stage ophthalmology compounds.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
How AI is reshaping ophthalmology in 2025 and beyond
2
Glaucoma 2026: Which emerging technologies will change practice?
3
Molecular insights and clinical experience: Extending anti-VEGF durability
4
8 things to know about aflibercept 8 mg for retinal vascular disease
5








































